Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001641172-25-026552
Filing Date
2025-09-04
Accepted
2025-09-04 13:53:27
Documents
1
Period of Report
2025-09-01

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 1537
  Complete submission text file 0001641172-25-026552.txt   3019
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Issuer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 800 W FLINT STREET CHANDLER AZ 85225
Business Address
Stazzone Peter (Reporting) CIK: 0002083297 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39717 | Film No.: 251292721